$AME

AMETEK (AME) Q2 2026 Earnings Call Transcript

AMETEK (AME) reported Q2 2026 net sales of $2.04B, up 15% year over year, with 10% organic growth. Adjusted EPS was $2.09, up 17%, above guidance of $1.96 to $2.00. Total orders were $2.3B, up 28%, backlog $4.11B. Full-year sales guidance rose about 10% and adjusted EPS to $8.20-$8.30.

Original reporting
Published Aug 11, 2026, 5:15 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 11, 2026, 5:38 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AMETEK (AME) Q2 2026 Earnings Call Transcript — source image
Decision brief

The 30-second read

$AMEBullishHigh
01

Why it matters

The combination of higher sales and EPS guidance, record orders/backlog, and improved working capital conversion provides a coherent upside earnings narrative for AMETEK.

02

Market read

Traders can use the raised FY and Q3 adjusted EPS ranges, record orders/book-to-bill, and margin and cash-flow improvements to reassess near-term earnings expectations.

03

What to watch

The text highlights a large acquisition and credit facility renewal, but does not quantify integration risks, customer concentration, or potential margin pressure from input costs.

Relevance 9/10Novelty 9/10Timing: post-earnings call, guidance and capital/credit updates for immediate repricing

Background

AMETEK’s Q2 2026 earnings call covers record orders, margin expansion, free cash flow, and updated full-year guidance plus acquisition and financing updates.

Company-level read

Ticker impact

$AMEBullishHigh confidence
Context

AMETEK reported Q2 2026 net sales of $2.04B, adjusted EPS $2.09, and raised full-year sales and EPS guidance.

Expected impact

Bullish bias for near-term trading as raised FY and Q3 EPS ranges confirm demand and margin momentum.

Evidence & confidence

The article discloses multiple decision-relevant datapoints: raised FY sales and adjusted EPS guidance, Q3 EPS guidance, record orders/book-to-bill, and margin and free-cash-flow expansion.

Market effects

Signals continued strength in industrial instrumentation and electronics tied to AI infrastructure, semiconductors, and defense modernization demand.

No specific regional demand signal beyond broad-based growth across AMETEK divisions.

Demand drivers cited (semiconductor manufacturing, hyperscaler data centers, defense modernization) are globally distributed end markets.

Counterpoint

Raised guidance could already be partially priced; investors may focus on acquisition integration and whether synergy assumptions (Indicor) are achievable.

Key entities

  • AMETEK, Inc.

    Reported Q2 2026 results and raised full-year sales and adjusted EPS guidance; discussed Indicor acquisition, margins, and credit facility renewal.

  • Indicor Instrumentation

    Planned acquisition expected to close in the second half of 2026, with management citing cost synergies.

  • Zygo

    AMETEK metrology and optical solutions business referenced as a semiconductor manufacturing growth driver.

  • RTDS Technologies

    AMETEK unit referenced as receiving an order from a data center hyperscaler for real-time digital simulation.

Related articles

$AMEMed

Segment Demand and Strategic Acquisitions Propel Growth

AMETEK (NYSE: AME) reported Q2 CY2026 revenue of $2.04 billion, up 15% year over year, beating Wall Street expectations. Non-GAAP EPS was $2.09, 4.8% above consensus. Management cited organic growth, rising orders and backlog of $4.11 billion, and contributions from acquisitions. Full-year guidance was raised, supported by AI, defense, and power grid demand.

$AMEMedAI 8/10

AMETEK, Inc. Q2 2026 Earnings Call Summary

AMETEK reported Q2 2026 momentum driven by multi-year infrastructure build-outs for AI, semiconductors, and power. Organic sales growth accelerated, with a record $4.11B backlog and about 80% expected to ship in 12 months. Core EMG margins rose 290 bps. Full-year 2026 organic sales guidance was raised to mid-to-high single digits; Indicor Instrumentation acquisition of $5B expected to close in H2 with 10% to 12% synergies.

$AMEHigh

AMETEK INC/ (AME): Results of Operations and Financial Condition

AMETEK INC/ (AME) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ametek8kexhibit99108042026.htm EX-99.1 Document Exhibit 99.1 AMETEK Announces Record Second Quarter 2026 Results and Raises Full Year Guidance Berwyn, Pa., Aug 4, 2026 – AMETEK, Inc. (NYSE: AME) today announced its financial results for the second quarter ended June 30,

$AMEMedAI 8/10

AMETEK’s (NYSE:AME) Q2 CY2026: Strong Sales

AMETEK (NYSE:AME) reported Q2 CY2026 revenue of $2.04 billion, up 15% year on year, exceeding Wall Street estimates by 4.4%, according to the company. Non-GAAP adjusted EPS was $2.09, up from $1.78 and 4.8% above consensus. Analysts expect full-year EPS of $8.46, up from $7.96.